Drug-coated balloons (DCBs) emerged as an alternative to bare metal stents and drug-eluting stents (DES) for the treatment of in-stent restenosis more than 10 years ago [ ]. DCBs provide a fast and high-dose delivery of antiproliferative drugs to the vessel wall and carry several anticipated benefits over DES, such as the lack of permanent scaffold and the need for a shorter duration of dual antiplatelet therapy. Good results from large registry studies and randomized clinical trials have encouraged the use of DCBs for de novo lesions [ , ]. However, the DCB-only strategy for de novo lesions is mainly restricted to small-vessel disease and high-bleeding-risk patients [ , ]. There was a discussion about late mortality of paclitaxel-related devices worldwide between 2018 and 2020 [ ]. Then the US Food and Drug Administration granted breakthrough device designation to three DCBs using sirolimus nanoparticles. Therefore, a comparison between new-generation DCBs in an all-comers population was warranted.
Cardiovascular Revascularization Medicine Volume 28, July 2021, Pages Pages 7-8
Read the full article on Science Direct: Drug-Coated Balloons for Coronary Artery Disease: First New-Generation Comparison of a Non-Widespread Technology